EUVIMED · CrossrefJournal
Journal of Hematology & Oncology
ISSN 1756-8722 · Springer Science and Business Media LLC
Latest articles
Adjuvant capecitabine-based oral chemotherapy plus trastuzumab as adjuvant therapy in patients with HER2-positive, node-negative breast tumors measuring 1 cm or smaller (ORCHID study)
Successful treatment of systemic light chain amyloidosis with a novel high-avidity BCMA CAR
Upfront venetoclax plus quizartinib with low-dose cytarabine or azacitidine in older unfit patients with acute myeloid leukemia: the phase I/II VEN-A-QUI trial
A phase Ia first-in-human study of BPB-101, a novel trifunctional antibody targeting the GARP/TGF-β complex and PD-L1, in patients with locally advanced or metastatic solid tumors
Futibatinib as a bridge to transplantation and post-transplant maintenance in blast-phase MLN-ZMYM2::FGFR1
PD-(L)1×VEGF bispecific antibodies in solid tumors: clinical trial updates from ASCO 2026
KRAS in pancreatic cancer: from molecular biology to transformative therapeutics
Plonmarlimab, a GM-CSF-neutralizing antibody, for macrophage activation syndrome
Global cancer statistics among older adults in 2024 with projections to 2050: a multi-source population-based analysis
T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis
Targeting cancer-associated fibroblasts: therapeutic strategies, translational challenges, and future perspectives
Glutathione reductase deficiency potentiates the immunogenicity of ferroptosis and cuproptosis via amplified reactive oxygen species accumulation and cGAS-STING pathway activation
High-definition spatial transcriptomics visualizes the cellular and molecular architecture underlying perineural invasion in localized prostate cancer
Current and future therapies for triple-negative breast cancer
A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm
Copper homeostasis and cuproptosis rewire the tumor microenvironment: mechanisms, immune modulation, and therapeutic opportunities
Dual-modular-nanobody CAR-T cell technical platform against the solid tumor microenvironment
Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm
The DAPK3-DCAF1 pathway regulates ZBP1 protein stability to orchestrate PANoptosis for ovarian cancer therapy
Tumor microenvironment–specific nanomedicine: from biology-driven to multi-omics–guided precision engineering
Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis
Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition)
Nanotechnology-enhanced CAR-T therapy strategies in cancer, aging, and autoimmune diseases
Cytokines and cancer-associated fibroblasts
Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming
Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies
Optimizing next-generation CAR-macrophages against solid tumors: challenges and potential strategies
Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase 3 trial
Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors
CXCR4-antagonistic peptide-decorated lipid nanoparticles for co- delivery of AML1-ETO siRNA to enhance chemotherapy in refractory AML
EUVIMED